1. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360-372, 2002
2. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
3. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. United Kingdom Prospective Diabetes Study Group (UKPDS 13). Br Med J 310:83-88, 1995
4. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
5. Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG: Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 5:353-363, 1982
6. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM: Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33:634-642, 1984
7. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985
8. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 16:21-31, 1993
9. Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA: Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes 51:462-468, 2002
10. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill V: Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26:2231-2237, 2003
11. Kosaka K, Kuzuya T, Akanuma Y, Hagura R: Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 18:23-28, 1980
12. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 20:1353-1356, 1997
13. Rosenstock J, Wyne K: Insulin treatment in type 2 diabetes. In Textbook of Type 2 Diabetes. Goldstein B, Müller-Wieland D, Eds. London, Martin Dunitz, 2003. Chapter 11, pp. 131-154
14. Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2:131-141, 1979
15. Malmberg K, Norhammar A, Wedel H, Ryden L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 99:2626-2632, 1999
16. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H: Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J 17:1337-1344, 1996
17. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UK Prospective Diabetes Study (UKPDS) Group (UKPDS 33). Lancet 352:837-853, 1998
18. Welle S, Nair KS, Lockwood D: Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus. J Clin Endocrinol Metab 66:593-597, 1988
19. Billingham MS, Milles JJ, Bailey CJ, Hall RA: Lipoprotein subfraction composition in non-insulin-dependent diabetes treated by diet, sulphonylurea, and insulin. Metabolism 38:850-857, 1989
20. Rivellese AA, Patti L, Romano G, Innelli F, Di Marino L, Annuzzi G, Iavicoli M, Coronel GA, Riccardi G: Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients. J Clin Endocrinol Metab 85:4188-4192, 2000
21. Cusi K, Cunningham GR, Comstock JP: Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 18:843-851, 1995
22. Emanuele N, Azad N, Abraira C, Henderson W, Colwell J, Levin S, Nuttall F, Comstock J, Sawin C, Silbert C, Marcovina S, Lee HS: Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med 158:2485-2490, 1998
23. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 90:450-459, 1991
24. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330-336, 2002
25. Holleman F, Hoekstra J: Insulin lispro. N Engl J Med 337:176-183, 1997
26. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L: Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23:583-588, 2000
27. Brunelle BL, Llewelyn J, Anderson JH, Jr., Gale EA, Koivisto VA: Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21:1726-1731, 1998
28. Heinemann L: Hypoglycemia and insulin analogues: is there a reduction in the incidence? J Diabetes Complications 13:105-114, 1999
29. Heller S, Amiel S, Mansell P: Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycaemia during intensified insulin therapy. Diabetes Care 22:1607-1611, 1999
30. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB: Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diab Care 22:468-477, 1999
31. Zinman B, Tildeslex H, Chaisson J-L: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46:440-443, 1997
32. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R: Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 22:784-788, 1999
33. Owens DR, Zinman B, Bolli GB: Insulins today and beyond. Lancet 358:739-746, 2001
34. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148, 2000
35. Heinemann L, Linkeschowa R, Rave K, Hompesch B, Sedalk M, Heise T: Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644-649, 2000
36. Scholtz H, Niekerk Nv, Meyer B, Rosenkranz B: An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique. Diabetologia 42(Suppl 1):Abstract 882, 1999
37. Pieber T, Eugene-Jolchine I, Derobert E: Efficacy and safety of HOE901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 23:157-162, 2000
38. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA: Less hypoglycemia with insulin glargine in intensive insulin therapy for Type 1 diabetes. Diabetes Care 23:639-643, 2000
39. Rosenstock J, Park G, Zimmerman J: Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 23:1137-1142, 2000
40. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666-1671, 2000
41. Mohn A, Strang S, Wernicke-Panten K, Lang A, Edge J, Dunger D: Nocturnal glucose control and free insulin levels in children with Type 1 diabetes by use of the long-acting insulin HOE901 as part of a three-injection regimen. Diabetes Care 23:557-559, 2000
42. Yki-Jarvinen H, Dressler A, Ziemen M: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23:1130-1136, 2000
43. Rosenstock J, Riddle M, Dailey G, Gerich J, Mecca T, Wilson C, Bugos C: Treatment to target study: feasibility of achieving control with the addition of basal bedtime insulin glargine (LANTUS) or NPH insulin in insulin-naive patients with Type 2 diabetes on oral agents. Diabetes 50(Suppl 2):A29. Abstract 520-P, 2001
44. Owens D, Coates P, Luzio S, Tinbergen J, Kurzhals R: Pharmacokinetics of [125]I- labelled insulin glargine (HOE 901) in healthy men. Diabetes Care 23:813-819, 2000
45. Barlocco D: Insulin detemir. Novo Nordisk. Curr Opin Investig Drugs 4:449-454, 2003
46. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, Larsen UD, Ribel U, Schaffer L, Vad K, Jonassen I: Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39:281-288, 1996
47. Pieber T, Plank J, Goerzer E, Sommer R, Wutte A, Sinner F, Bodenlenz F, Endahl L, Draeger E: Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with Type 1 diabetes. Diabetes 51(Suppl 2):A53, 2002
48. D'Eliseo P, Blaauw J, Milicevic Z, Wyatt J, Ignaut DA, Malone JK: Patient acceptability of a new 3.0 ml pre-filled insulin pen. Curr Med Res Opin 16:125-133, 2000
49. Gall MA, Mathiesen ER, Skott P, Musaeus L, Damm S, Beck-Nielsen H, Parving HH: Effect of multiple insulin injections with a pen injector on metabolic control and general well-being in insulin-dependent diabetes mellitus. Diabetes Res 11:97-101, 1989
50. Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T: Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 23:1343-1347, 2000
51. Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH: Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 163:2277-2282, 2003
52. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
53. Lee W, Zinman B: From insulin to insulin analogs: progress in the treatment of type 1 diabetes. Diabetes Reviews 6:73-88, 1998
54. Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL: The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:737-745, 2001
55. Goldstein B, Bruce S, Lee H, Fiedorek F: Rosiglitazone added to glyburide/metformin tablets: glycemic effects. Diabetes 51(Suppl 2):A98. Abstract 398, 2002
56. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P, on behalf of the INS-2061 Study Group: Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral agents. Diabetes Care 26:2238-2243, 2003
57. Riddle M: Timely addition of insulin to oral therapy for Type 2 diabetes. Diabetes Care 25:395-396, 2002
58. Holman RR, Steemson J, Turner RC: Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabet Med 4:457-462, 1987
59. Shank ML, Del Prato S, DeFronzo RA: Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes 44:165-172, 1995
60. Yki-Jarvinen H, Ryysey L, Nikkila K, Tulokas T, Vanamo R, Heikkila M: Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med 130:389-396, 1999
61. Fritsche A, Shweltzer MA, Häring H, on behalf of the 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med. 138:952–959, 2003
62. Riddle M, Rosenstock J, Gerich J, on behalf of the Insulin Glargine 4002 Study Investigators: The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care 26:3080-3086, 2003
63. Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE: Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 23:1236-1241, 2000
64. Rosenstock J, on behalf of the Exubera Phase III Study Group: Mealtime rapid-acting inhaled insulin (Exubera) improves glycemic control in patients with type 2 diabetes failing oral agents: a 3-month, randomized, comparative trial. Diabetes 51(Suppl 2):A132, 2002
65. Hamann A, Matthaei S, Rosak C, Silvestre L, on behalf of the HOE901/4007 Study Group: A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with Type 1 diabetes. Diabetes Care 26:1738-1744, 2003